Ver­tex and CRISPR spot­light an­oth­er im­por­tant gene edit­ing ad­vance in a march to a hoped-for cure

Ver­tex and CRISPR Ther­a­peu­tics have suc­cess­ful­ly nav­i­gat­ed an­oth­er stretch of the maid­en clin­i­cal jour­ney of the gene edit­ing ther­a­py CTX001 in a tiny group of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER